About the Project
Although bariatric surgery is currently recommended as a treatment option for T2D by the International Diabetes Federation and American Diabetes Association, only a very small percentage of T2D patients is currently using this therapeutic option. This is partly due to its highly invasive nature, and more importantly, owing to the fact that the remission rate is only 74.2% after 1 year, and further dropped to 57.6% after 3 years in Chinese population. Furthermore, the recurrence of T2D in some patients has also been reported in long-term studies. There is currently no reliable predictive and prognostic biomarker(s) for the clinical outcome of bariatric surgery.
The overall goal of the study is to identify sensitive biomarker(s) that is predictive for the metabolic outcomes of bariatric surgery in obese Chinese with T2D and to unveil the molecular basis underlying the adiposity-independent benefits on T2D. To achieve this, two prospective study cohorts in Chinese have been employed, including one 5-year follow-up bariatric surgery cohort consisting of 120 obese patients with T2D, and another prospective biobank of obese individuals with or without T2D undergone bariatric surgery. The serum/urine samples, together with subcutaneous and visceral adipose tissue biopsies from these two cohorts, at both baseline and year-5, will be used for proteomics/metabolomics analysis to search for novel predictive biomarkers or metabolites for the remission of T2D. The findings will be replicated and cross-validated in a bariatric surgery cohort recruited in Germany. Following that, the molecular mechanisms whereby these markers contribute to pathogenesis of T2D will be examined using animal and cell-based studies. The implementation of the study will characterize new strategies to predict the prognosis of bariatric surgery and its molecular basis, and provide new insight to development of novel therapies that mimic metabolic benefits of bariatric surgery.
SupervisorProfessor Aimin Xu has been focusing on both basic and translational research on obesity/diabetes-related disorders. He is leading the State Key Laboratory of Pharmaceutical Biotechnology, which is at the forefront of innovation and discovery in the field of molecular metabolism, with a focus on hormones and biomarkers (www.sklpb.hku.hk). Professor Xu has made significant contributions to discovery and functional characterization of several adipokines and hormones including adiponectin, fibroblast growth factor 21 (FGF21), adipocyte-fatty acid binding protein (A-FABP) and lipocalin-2. For recent publications from his group, please visit https://scholar.google.com/citations?user=vyPfQmIAAAAJ&hl=en
Faculty information, funding opportunities and application deadlines: https://www.findaphd.com/phds/program/biomedical-research-hku-li-ka-shing-faculty-of-medicine/?i586p4119
Why not add a message here
Based on your current searches we recommend the following search filters.
Based on your current search criteria we thought you might be interested in these.
Human fat distribution and metabolic disease: Identifying the mechanistic basis for site-specific fat storage to identify new ways of tackling the metabolic consequences of obesity.
University of Oxford